[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100569398":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":32,"studyPopulation":25,"armGroups":33,"interventions":39,"overallOfficials":25,"centralContacts":44,"locations":50,"responsibleParty":69,"collaborators":25,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":25,"studyType":87,"phases":88,"briefSummary":90,"conditions":91,"keywords":93,"overallStatus":53,"whyStopped":25,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Iowa","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":25},[9],{"measure":10,"description":11,"timeFrame":12},"Feasibility of completing all clinical trial activities","Percentage of patients who provide informed consent and receive angiotensin II infusion in the emergency department","From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated",[14,18,21],{"measure":15,"description":16,"timeFrame":17},"Mean arterial pressure response","Change in mean arterial pressure","60 minutes after the intiation of angiotensin II infusion",{"measure":19,"description":20,"timeFrame":17},"Mean norepinephrine dose (during angiotensin II infusion)","Change in norepinephrine dose (mcg\u002Fkg\u002Fminute) after the initiation of angiotensin II infusion",{"measure":22,"description":23,"timeFrame":24},"Mean norepinephrine dose (post angiotensin II infusion)","Mean norepinephrine dose (mcg\u002Fkg\u002Fminute) after the completion of the angiotensin II infusion","60 minutes after the completion of the angiotensin II infusion",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":25,"primaryPurpose":29,"observationalModel":25,"timePerspective":25,"maskingInfo":30},"NON_RANDOMIZED","SINGLE_GROUP","TREATMENT",{"masking":31,"maskingDescription":25,"whoMasked":25},"NONE","Following informed consent, patients will receive intravenous angiotensin II (AT-II) infusion for blood pressure support. The patient will remain on the AT-II infusion for 60 minutes prior to determining patient response which will be determined by recording the concurrent dose of norepinephrine and MAP every 10 minutes from initiation. If a positive response (e.g., norepinephrine dose reduction) is witnessed, the AT-II infusion will be titrated off after a maximum of 6 hours or when infusion is completed, whichever occurs first.",[34],{"label":35,"type":36,"description":25,"interventionNames":37},"Angiotensin II Infusion","EXPERIMENTAL",[38],"Drug: Angiotensin II Infusion",[40],{"type":41,"name":35,"description":42,"armGroupLabels":43,"otherNames":25},"DRUG","Angiotensin II continuous infusion",[35],[45],{"name":46,"role":47,"phone":48,"phoneExt":25,"email":49},"Brett Faine, PharmD","CONTACT","+1 319 356 2577","brett-faine@uiowa.edu",[51],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"University of Iowa Hospitals and Clinics","RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-91.53017,41.66113,{"lat":63,"lon":62},[66],{"name":67,"role":47,"phone":68,"phoneExt":25,"email":49},"Brett Faine","3193108067",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Brett A Faine","Clinical Associate Professor","100569398","phase-4-early-angiotensin-ii-in-the-emergency-department-100569398",false,"NCT06693726","Early Angiotensin II in the Emergency Department","ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study","ANGIO-ED","Inclusion Criteria\n\n1. Age ≥18; and\n2. Requiring norepinephrine at a dose of 0.05-0.25 mcg\u002Fkg\u002Fmin mcg\u002Fkg\u002Fminute despite adequate fluid resuscitation; and\n3. Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and\n4. Can provide written informed consent (or legally authorized representative).\n\nExclusion Criteria\n\n1. Acute coronary syndrome;\n2. Cardiogenic shock;\n3. Patients with a history of mesenteric ischemia;\n4. Patients with a history of having an aortic dissection or abdominal aortic aneurysm;\n5. Patients with an expected lifespan of \\\u003C12 hours;\n6. Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);\n7. Active administration of two vasoactive agents before enrollment; and\n8. Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.","ALL","18 Years","99 Years",{"count":85,"type":86},20,"ESTIMATED","INTERVENTIONAL",[89],"PHASE4","This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED",[92],"Septic Shock",[94],"Angiotensin II","2026-09-01",{"date":97,"type":98},"2026-09-02","ACTUAL",{"date":100,"type":98},"2025-04-01",{"date":102,"type":86},"2027-01-30",{"name":71,"class":6},1]